Relationships between EGFR mutation status of lung cancer and preoperative factors - Are they predictive?

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 2, 2014, Pages 657-662

  Usuda, Katsuo ^a   Sagawa, Motoyasu ^a   Motono, Nozomu ^a   Ueno, Masakatsu ^a   Tanaka, Makoto ^a   Machida, Yuichiro ^a   Matoba, Munetaka ^a   Taniguchi, Mitsuru ^a   Tonami, Hisao ^a   Ueda, Yoshimichi ^a   Sakuma, Tsutomu ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Discriminant analysis; EGFR mutation; Ground glass opacity; Lung cancer; PET CT

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; CANCER STAGING; COLLOID CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; GENETICS; HUMAN; LARGE CELL CARCINOMA; LUNG TUMOR; MALE; MUTATION; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; AGED; CARCINOMA, LARGE CELL; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE CARE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84894648693     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.2.657     Document Type: Article

References (24)

1. Dwamena BA, Sonnad SS, Angobaldo JO, et al (1999). Metastases from non-small cell lung cancer. Mediastinal staging in the 1990s. Meta-analytic comparison of PET and CT. Radiology, 213, 530-6.
2. Hsieh RK, Lim KH, Kuo HT, et al (2005). Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest, 128, 317-21.
3. International Union Against Cancer (2009). TNM classification of malignant tumours. 7th ed. NY, Wiley-Liss, 138-46.
4. Jorissen RN, Walker F, Pouliot N, et al (2003). Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res, 284, 31-53.
5. Kitamura H, Kameda Y, Ito T, Hayashi H (1999). Atypical adenomatous hyperplasia of the lung. Implications for the pathogenesis of peripheral lung adenocarcinoma. Am J Clin Pathol, 111, 610-22.
6. Le Bihan D, Breton E, Lallemand D, et al (1988). Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology, 168, 497-505.
7. Lee HY, Lee KS (2011). Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging, 26, 106-18.
8. Liu WS, Zhao LJ, Pang QS, et al (2014). Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas. Med Oncol, 31, 771.
9. Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
10. Mak RH, Digumarthy SR, Muzikansky A, et al (2011). Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer. Oncologist, 16, 319-26.
11. Mclntire MG, Santagata S, Ligon K, Chirieac LR (2010). Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. Am J Transl Res, 2, 309-15.
12. Miller VA, Kris MG, Shah N, et al (2004). Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol, 22, 1103-9.
13. Mori T, Nomori H, Ikeda K, et al (2008). Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses. Comparison with positron emission tomography. J Thoracic Oncol, 3, 358-64.
14. Na II, Byun BH, Kim KM, et al (2010). 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis. Lung Cancer, 67, 76-80.
15. Nasu K, Kuroki Y, Kuroki S, et al (2004). Diffusion-weighted single shot echo planar imaging of colorectal cancer using a sensitivity-encoding technique. Jpn J Clin Oncol, 34, 620-26.
16. Paez JG, Jänne PA PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
17. Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.
18. Raz DJ, He B, Rosell R, Jablons DM (2006). Bronchioloalveolsr carcinoma. A review. Clinical Lung cancer, 7, 313-22.
19. Sun PL, Seol H, Lee HJ, et al (2012). High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol, 7, 323-30.
20. Tam IYS, Chung LP, Suen WS, et al (2006). Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res, 12, 1647-53.
21. Toloza EM, Harpole L, McCrory DC (2003). Noninvasive staging of non-small cell lung cancer. Chest, 123, 137-46.
22. Travis WD, Brambilla E, Noguchi M, et al (2011). International association for the study of lung cancer/ american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 6, 244-85.
23. Usuda K, Zhao XT, Sagawa M, et al (2013). Diffusion-weighted imaging (DWI) signal intensity and distribution represent the amount of cancer cells and their distribution in primary lung cancer. Clinical Imaging, 37, 265-72.
24. Yoshizawa A, Motoi N, Riely GJ, et al (2011). Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol, 24, 653-64.